BBIO vs RL · rev $221.9M vs P/E 24, rev $8.11B
BridgeBio Pharma Inc (BBIO) versus Ralph Lauren Corp Class A (RL) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Ralph Lauren Corp Class A (RL) is a apparel manufacturing company listed on US.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported RL revenue for 2026-03-28 was $8.11B. Net income was $941.1M. Revenue was up 14.6% from 2025-03-29 to 2026-03-28. RL currently screens at market cap $16.95B and trailing P/E 24.1.
BBIO currently screens at market cap $13.24B. RL currently screens at market cap $16.95B and trailing P/E 24.1.
Not investment advice. Open the BBIO and RL stock pages for the full models.
Not investment advice.